Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors

Gauthier S., Emre M., Farlow M., Bullock R., Grossberg G., Potkin S.

CURRENT MEDICAL RESEARCH AND OPINION, cilt.19, sa.8, ss.707-714, 2003 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 8
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1185/030079903125002450
  • Dergi Adı: CURRENT MEDICAL RESEARCH AND OPINION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.707-714
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Cholinesterase (ChE) inhibitors represent the standard therapeutic approach to the treatment of Alzheimer's disease (AD). However, a proportion of patients experience lack or loss of therapeutic benefit with an initial agent, or discontinue due to safety/tolerability issues. In many instances, no alternative treatment is offered once the initial agent has been stopped. Thus, for many patients, the total duration of treatment is relatively short in comparison with the chronic nature of AD.